MCFUF yields 67.97% · PFE yields 6.13%● Live data
📍 MCFUF pulled ahead of the other in Year 1
Combined, MCFUF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MCFUF + PFE for your $10,000?
Micro Focus International plc operates in the enterprise software business in the United Kingdom, the United States, Germany, Canada, France, Japan, and internationally. It offers infrastructure software products that are managed on a portfolio. The company's product portfolio includes sector-agnostic products, such as application modernization and connectivity solutions that help customers to unlock the value from core business applications for modernization, which enable a transformational journey to deliver ongoing value and flexibility from IT investments, on or off the mainframe; application delivery management solutions that helps customers to increase velocity, remove bottlenecks, and deliver high-performing applications to support their digital business; and IT operations management solutions for service assurance, automate the service fulfilment life cycle, and strengthen IT service governance. It also offers CyberRes, a security solution that helps enterprises to create cyber resilience through detecting threats, securing data and applications, and protecting identities, which enables customers to adapt and evolve for the future; and information management and governance solutions that helps customers to analyze, understand, and control data to derive value and manage enterprise risk. The company was founded in 1976 and is headquartered in Newbury, the United Kingdom.
Full MCFUF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.